SAN

73.08

-1.07%↓

ARGX

680.6

-4.6%↓

SHL.DE

33.74

-1.23%↓

PHIA

21.83

-0.86%↓

FRE

35.85

-0.17%↓

SAN

73.08

-1.07%↓

ARGX

680.6

-4.6%↓

SHL.DE

33.74

-1.23%↓

PHIA

21.83

-0.86%↓

FRE

35.85

-0.17%↓

SAN

73.08

-1.07%↓

ARGX

680.6

-4.6%↓

SHL.DE

33.74

-1.23%↓

PHIA

21.83

-0.86%↓

FRE

35.85

-0.17%↓

SAN

73.08

-1.07%↓

ARGX

680.6

-4.6%↓

SHL.DE

33.74

-1.23%↓

PHIA

21.83

-0.86%↓

FRE

35.85

-0.17%↓

SAN

73.08

-1.07%↓

ARGX

680.6

-4.6%↓

SHL.DE

33.74

-1.23%↓

PHIA

21.83

-0.86%↓

FRE

35.85

-0.17%↓

Home・Listă Acțiuni・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Deschisă

SectorSănătate

57.45 -0.52

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

57.35

Maxim

57.95

Indicatori cheie
By Trading Economics
Venit	-33M 9.5M
Vânzări	-66M 152M
P/E Medie Sector	24.47 49.888
EPS	0.185
Marjă de profit	6.216
Angajați	1,950
EBITDA	-45M 18M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+25.92% upside

Dividende
By Dow Jones
Următoarele câștiguri	23 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.1B 3B
Deschiderea anterioară	57.97
Închiderea anterioară	57.45

Sentimentul știrilor

By Acuity

50%

147 / 344 Clasament în Healthcare

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2026, 20:30 UTC

Câștiguri

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 iun. 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 iun. 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 iun. 2026, 23:00 UTC

Achiziții, Fuziuni, Preluări

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 iun. 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 iun. 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 iun. 2026, 21:00 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 iun. 2026, 20:46 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:38 UTC

Câștiguri

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 iun. 2026, 20:21 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:12 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Product Rev $594M

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Loss $177M >PANW

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

25.92% sus

Prognoză pe 12 luni

Medie 73.6 EUR 25.92%

Maxim 83 EUR

Minim 64.2 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Laboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Sentiment

By Acuity

147 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.